Vindon Healthcare (LON:VDN) , the provider of controlled environment services and products, announced its interim results for the six months to 30 June 2010. The group managed a modest 2% increase in revenues to £2.6 million - good progress in the services business was countered by slow equipment sales. Profits were also down slightly, principally due to costs associated with the Westech relocation/integration in the US. In the UK and Ireland, the company's core market is supplying managed storage facilities for pharmaceutical stability studies. These studies are a mandatory part of gaining approval to sell new pharmaceutical products, and can last three years. This business is progressing well, and the company has £1 million in contracted revenue for H2 and £1.2 million for 2011 so far. Vindon is building a new storage facility in the US to focus on pharma stability studies - replicating the successful business model in Ireland of providing storage services along with sales and support of the company's OEM equipment. The VDN share price has declined by 36% over the last year. Vindon Healthcare Plc is currently graded b by LCF Research.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here